SNDX
Syndax Pharmaceuticals, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
32.55
P/S
12.43
EV/EBITDA
-10.66
DCF Value
$15.48
FCF Yield
-15.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
96.0%
Operating Margin
-158.4%
Net Margin
-165.6%
ROE
-206.6%
ROA
-53.9%
ROIC
-66.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $68.5M | $-68.0M | $-0.78 |
| FY 2025 | $172.4M | $-285.4M | $-3.30 |
| Q3 2025 | $45.9M | $-60.7M | $-0.70 |
| Q2 2025 | $38.0M | $-71.8M | $-0.83 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.41
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.